STOCK TITAN

DBV Technologies S.A. (DBVT) Stock Price, News & Analysis

DBVT NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
50 252 sessions, November 20, 2025 to November 20, 2026
Largest daily move
+25.4% close of December 17, 2025
1-year change
-34.5% closing prices, November 20, 2025 to November 20, 2026
1-month change
-4.9% closing prices, October 20, 2026 to November 20, 2026

Company Description

DBV Technologies S.A. (NASDAQ: DBVT; Euronext Paris: DBV) is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. According to the company’s disclosures, DBV Technologies is focused on investigating the use of its proprietary Viaskin patch technology and epicutaneous immunotherapy (EPIT) to address food allergies, which are caused by a hypersensitive immune reaction and can lead to symptoms ranging from mild discomfort to life-threatening anaphylaxis. The company is headquartered in Châtillon, France, and has North American operations in Warren, New Jersey.

DBV Technologies’ core technology platform is Viaskin, a skin patch designed to deliver microgram amounts of a biologically active compound to the immune system through intact skin. The therapeutic approach, called epicutaneous immunotherapy (EPIT), is described by the company as a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to an allergen. EPIT leverages the skin’s immune tolerizing properties to promote desensitization while avoiding direct injection or ingestion of the allergen.

Focus on food allergy treatments

DBV Technologies states that millions of people live with food allergies, including young children, and that current options are limited, often relying on strict avoidance and emergency management of reactions. The company is developing product candidates that aim to offer new treatment options for these patients. Its food allergy programs include ongoing clinical trials of Viaskin Peanut in peanut-allergic toddlers aged 1 through 3 years and children aged 4 through 7 years.

The company has highlighted Viaskin Peanut as its main product candidate. In company communications, Viaskin Peanut is being evaluated as a potential treatment for peanut-allergic children using the Viaskin patch platform. DBV Technologies reports that its pivotal Phase 3 VITESSE trial of the Viaskin Peanut patch in peanut-allergic children aged 4 to 7 years met its primary endpoint, and that safety results were consistent with the safety profile observed in the Viaskin Peanut clinical program to date. The company has also described VITESSE as a large, randomized, double-blind, placebo-controlled study in this patient population.

Epicutaneous immunotherapy (EPIT) approach

DBV Technologies explains that through EPIT, the Viaskin patch is designed to introduce very small quantities of allergen or other biologically active compounds to the immune system via intact skin. The goal is to gradually desensitize the immune system to the allergen over time. The company characterizes EPIT as non-invasive and focused on modifying the underlying allergy rather than only treating acute reactions. This approach is central to DBV Technologies’ strategy for food allergy and other immunologic conditions.

Pipeline and clinical programs

In its public materials, DBV Technologies describes itself as a clinical-stage or late-stage biopharmaceutical company. Its food allergy programs include:

  • Ongoing clinical trials of Viaskin Peanut in peanut-allergic toddlers (1 through 3 years of age).
  • Ongoing clinical trials of Viaskin Peanut in peanut-allergic children (4 through 7 years of age), including the Phase 3 VITESSE trial.

The company has also referred to a supplemental safety study (COMFORT Toddlers) in peanut-allergic toddlers aged 1 to 3 years, indicating continued clinical investigation in this younger age group. Earlier descriptions of DBV Technologies’ activities reference additional food allergy programs, such as Viaskin Milk and work related to eosinophilic esophagitis, but the company’s most recent communications emphasize Viaskin Peanut and its associated clinical trials.

Stock listings and corporate structure

DBV Technologies’ ordinary shares trade on segment B of Euronext Paris under the ticker symbol DBV, with ISIN code FR0010417345. The company’s American Depositary Shares (ADSs), each representing five ordinary shares, trade on the Nasdaq Capital Market under the symbol DBVT (CUSIP: 23306J309). The company has also reported information on its total number of shares and voting rights in accordance with the regulations of the Autorité des Marchés Financiers in France.

Through its dual listing on Euronext Paris and Nasdaq, DBV Technologies provides access to both European and U.S. investors. The company has used equity financing tools, including warrants and at-the-market offerings of ADSs, as described in its regulatory filings, to support its clinical development and corporate activities.

Regulatory and clinical milestones

DBV Technologies has reported several notable regulatory and clinical developments related to Viaskin Peanut. The company has stated that the U.S. Food and Drug Administration (FDA) previously granted Breakthrough Therapy Designation for the Viaskin Peanut patch. It has also indicated its intention to submit a Biologics License Application (BLA) in the United States for Viaskin Peanut in children aged 4 to 7 years, followed by a planned submission for toddlers aged 1 to 3 years, aligning these plans with the positive topline results from the VITESSE Phase 3 trial.

In addition to clinical and regulatory updates, DBV Technologies periodically reports financial results, business highlights, and corporate governance changes, such as appointments and resignations of directors and senior executives, through press releases and SEC filings.

Geographic footprint

DBV Technologies is based in Châtillon, France, and notes that it maintains North American operations in Warren, New Jersey. Its clinical trials, including the VITESSE Phase 3 study, have involved sites in the United States, Canada, the United Kingdom, Europe, and Australia, reflecting a global clinical development footprint as described in company communications.

Summary

According to its public statements, DBV Technologies S.A. is focused on developing non-invasive, EPIT-based treatments for food allergies, with Viaskin Peanut as its lead program in peanut-allergic toddlers and children. The company’s Viaskin patch platform, regulatory interactions, and late-stage clinical trials form the core of its business profile as a clinical-stage biopharmaceutical issuer listed on Euronext Paris and the Nasdaq Capital Market.

Stock Performance

$9.02
-4.25%
-0.40
Last updated: at
-34.5%
Performance 1 year
$566.8M

DBV Technologies S.A. (DBVT) closed at $9.02 on November 20, 2026. Over the past 12 months, the price has lost 34.5%.

See what a $1,000 investment in DBVT would be worth today

Average down calculator for DBVT

DBVT Metrics & Rankings

Price returns through November 20, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

DBV Technologies S.A. has 10 recent news articles. Of the recent coverage, 4 articles coincided with positive price movement and 6 with negative movement. Key topics include clinical trial, earnings, earnings date. View all DBVT news →

Financial Highlights

DBV Technologies S.A. generated $5.6M in revenue in FY2025, operating income reached -$147.1M, and net income was -$146.9M. Diluted earnings per share stood at -$1.05. The company generated -$121.2M in operating cash flow. The current ratio was 3.67, measuring current assets divided by current liabilities.

$5.6M
Revenue (FY2025)
-$146.9M
Net Income (FY2025)
-$121.2M
Operating Cash Flow

Upcoming Events

YEAR
2027
2027 Regulatory

Toddler application submission

DBV Technologies S.A. expects to submit U.S. marketing application for VIASKIN Peanut in toddlers ages 1–3 sometime in 2027.
Q2
2027
Q2 2027 Financial

Cash runway through Q2 2027

Company reports cash runway into Q2 2027; may require financing before end of period
Q2
2027
Q2 2027 Financial

Cash runway milestone

Company reports $229M cash as of 2026-03-31, funding operations into Q2 2027; potential financing or dilution risk then.

DBV Technologies S.A. has 3 upcoming scheduled events. The next event, "Toddler application submission", is expected in 2027. 2 of them are financing or capital events, such as a dividend or a debt maturity. Investors can track these dates to stay informed about potential catalysts that may affect the DBVT stock price.

Short Interest History

Last 12 Months

Short interest in DBV Technologies S.A. (DBVT) currently stands at 806.7 thousand shares, down 7.5% from the previous reporting period, representing 1.3% of the float. Since November 2025, short interest has increased by 2402.8%.

Days to Cover History

Last 12 Months

Days to cover for DBV Technologies S.A. (DBVT) currently stands at 1.7 days, down 16.1% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 67%. Across the settlements charted above, it has ranged from 1.0 to 10.1 days.

DBVT Company Profile & Sector Positioning

DBV Technologies S.A. (DBVT) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing DBVT often look at related companies in the same sector, including Achieve Life Sciences, Inc. (ACHV), ArriVent BioPharma, Inc. (AVBP), Bicara Therapeutics Inc. (BCAX), Annexon, Inc. (ANNX), and Aura Biosciences, Inc. (AURA). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate DBVT's relative position within its industry.

Frequently Asked Questions

The current stock price of DBV Technologies S.A. (DBVT) is $9.02 as of November 20, 2026.

The market cap of DBV Technologies S.A. (DBVT) is approximately $566.8M. Learn more about what market capitalization means .

The FY2025 revenue of DBV Technologies S.A. (DBVT) is $5.6M, from its most recent completed fiscal year.

The FY2025 net income of DBV Technologies S.A. (DBVT) is -$146.9M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of DBV Technologies S.A. (DBVT) is -$1.05 for FY2025, its most recent completed fiscal year. DBVT trades in the US as American depositary shares (ADSs), and one ADS represents 5 ordinary shares. We could not tell from the filings whether the per-share figures and share counts here are per ordinary share or per ADS. Learn more about EPS .

The operating cash flow of DBV Technologies S.A. (DBVT) is -$121.2M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The current ratio of DBV Technologies S.A. (DBVT), current assets divided by current liabilities, was 3.67 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The operating income of DBV Technologies S.A. (DBVT) is -$147.1M for FY2025, its most recent completed fiscal year. Learn about operating income.

DBV Technologies S.A. is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. It is focused on using its proprietary Viaskin patch technology and epicutaneous immunotherapy (EPIT) to help desensitize patients to specific allergens.

The Viaskin patch is DBV Technologies’ proprietary technology platform designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. It is used in epicutaneous immunotherapy (EPIT), a non-invasive approach that aims to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to an allergen.

DBV Technologies is focusing on food allergies, which it describes as hypersensitive immune reactions that can cause symptoms from mild to life-threatening anaphylaxis. Its food allergy programs include ongoing clinical trials of Viaskin Peanut in peanut-allergic toddlers aged 1 through 3 years and children aged 4 through 7 years.

Viaskin Peanut is DBV Technologies’ lead product candidate being developed for peanut-allergic patients. It uses the Viaskin patch platform to deliver small amounts of peanut protein through the skin as part of epicutaneous immunotherapy, with the goal of desensitizing the immune system. The company has reported ongoing clinical trials in toddlers and children with peanut allergy.

Epicutaneous immunotherapy (EPIT) is DBV Technologies’ proprietary method of delivering biologically active compounds to the immune system through intact skin using the Viaskin patch. The company describes EPIT as a new class of non-invasive treatment that seeks to modify an underlying allergy by leveraging the skin’s immune tolerizing properties to desensitize patients to specific allergens.

DBV Technologies states that it is headquartered in Châtillon, France, and that it has North American operations in Warren, New Jersey.

DBV Technologies’ ordinary shares are traded on segment B of Euronext Paris under the ticker DBV with ISIN code FR0010417345. Its American Depositary Shares, each representing five ordinary shares, are traded on the Nasdaq Capital Market under the symbol DBVT with CUSIP 23306J309.

The VITESSE study is a global Phase 3, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of the Viaskin Peanut patch 250 µg in peanut-allergic children aged 4 to 7 years. DBV Technologies reports that VITESSE enrolled 654 children and that the trial met its primary endpoint, with safety results consistent with the existing Viaskin Peanut clinical program.

In reporting topline results from the VITESSE Phase 3 trial, DBV Technologies stated that safety results were consistent with the safety profile observed in the Viaskin Peanut clinical program to date. The most common treatment-emergent adverse events were described as mild-to-moderate local skin reactions at the patch application site, with low discontinuation rates and low reported rates of treatment-related anaphylaxis.

DBV Technologies has stated that the U.S. Food and Drug Administration previously granted Breakthrough Therapy Designation for the Viaskin Peanut patch. The company has also indicated plans to submit a Biologics License Application (BLA) for Viaskin Peanut in specific pediatric age groups.